Core Viewpoint - The A-share market in 2026 is expected to exhibit structural characteristics driven by leading companies and fundamentals, focusing on opportunities in cycles, technology, and pharmaceuticals, as well as the theme of companies going global [1][3]. Fundamental Drivers - The current global economic landscape is undergoing significant adjustments, with a focus on high-quality development in the domestic economy. The selection of stocks should meet four core criteria: potential returns, competitive barriers, short-term demand changes leading to growth, and significant long-term growth potential [2][3]. Market Outlook - The A-share market is anticipated to show a pronounced concentration of leading companies and fundamental-driven characteristics. This will manifest in three dimensions: a highly structured market favoring a few companies with real and sustainable performance; leading companies with strong barriers and growth; and a focus on fundamentals where market pricing will closely align with companies' growth capabilities over the next one to two years [3]. Opportunities in Segmented Fields - The investment team is exploring opportunities in segmented fields, particularly in cycles, technology, and pharmaceuticals. The focus on cycles is driven by the bottoming out of corporate capacity and policies promoting absolute capacity clearance, with demand supported by various factors including potential interest rate cuts overseas and strong infrastructure needs in emerging markets [4][6]. Specific Focus Areas - In the cyclical sector, four key areas are highlighted: non-ferrous metals, aluminum, lithium carbonate driven by energy storage, and chemical products with improving supply-demand dynamics. The technology sector remains a primary focus, with strong investment interest and clear demand signals emerging [6][7]. Pharmaceutical Sector Insights - The pharmaceutical industry is centered on innovation and global expansion, with significant potential in the innovative drug sector, particularly in dual-antibody and small nucleic acid therapies. The medical device sector is also gaining attention, especially in surgical robotics and AI applications in healthcare [7][8]. Global Expansion Strategy - The theme of "going global" is emphasized, focusing on companies capable of moving into high-value sectors and possessing brand strength and global competitiveness. Key selection criteria include capacity for overseas production, technological and brand capabilities, and cultural outreach [8][9]. Performance of Companies with Global Revenue - Companies with a higher proportion of overseas revenue tend to show greater resilience and growth potential. As the global manufacturing sector may enter a replenishment cycle, Chinese manufacturing firms with global competitive advantages are expected to expand their market share through international ventures [9].

Core Viewpoint - The A-share market shows strong momentum entering 2026, with the pharmaceutical sector rebounding significantly, as evidenced by the 7.81% increase in the pharmaceutical and biotechnology index in just five trading days [1][23]. Group 1: Fund Performance - The E Fund Healthcare Fund has outperformed the industry index with a net value increase of 16.85% in the same period [1][23]. - Since manager Yang Zhenshao took over in August 2016, the fund has achieved a return of 237.49% and an annualized return of 13.81% [1][23]. - The fund has consistently outperformed the pharmaceutical and biotechnology index for nine consecutive years since 2017, demonstrating the manager's value [1][23]. Group 2: Investment Strategy - Yang Zhenshao's investment approach combines macro and micro perspectives, focusing on industry cycle positions and trends while pursuing long-term alpha through bottom-up balanced allocation [26][30]. - The fund maintains a high stock position, typically over 92%, with a relatively low turnover rate, indicating a long-term investment style [27][28]. - The strategy emphasizes the importance of deep research to support long-term holdings, which helps avoid excessive trading and capitalizes on systematic industry growth opportunities [28][30]. Group 3: Market Trends and Opportunities - Yang Zhenshao is keenly aware of new industry trends, having positioned the fund in advance of the recent surge in innovative drugs, which has contributed to the fund's strong performance [30][34]. - The pharmaceutical index has shown a significant long-term growth of 1090.57% over the past 20 years, far exceeding the 401.52% growth of the CSI 300 index [30][31]. - The current focus is on the innovative drug sector, which is expected to recover in liquidity, providing attractive opportunities for quality asset allocation [40][42]. Group 4: Future Outlook - The strategy remains to pursue stable excess returns while dynamically adjusting allocation ratios based on the economic conditions of various pharmaceutical sub-sectors [39][40]. - The launch of the new E Fund Hong Kong Stock Connect Healthcare Mixed Fund aims to capture the global benefits of China's pharmaceutical innovation [43][44]. - Yang Zhenshao's proven track record and deep research background position him as a valuable asset in navigating the evolving pharmaceutical investment landscape [44].

Core Viewpoint - Wang Zheyu, the Vice President and Board Secretary of Zhendong Pharmaceutical, submitted his resignation due to a job transfer, although he will continue to hold other positions within the company. His early departure raises questions about potential changes in company plans [1][5]. Group 1: Career Progression - Wang Zheyu's career trajectory shows a clear path from the pharmaceutical industry to capital investment and back to pharmaceuticals, indicating a strong understanding of both sectors [1]. - From 2012 to 2017, he gained experience in the pharmaceutical industry at Yabao Pharmaceutical, where he learned to analyze the industry and participate in project investments [2]. - He later became an Investment Director at Songshan Capital, focusing on identifying and managing investments in the pharmaceutical and consumer sectors [2]. - Between 2017 and 2022, he worked at Tianfeng Securities and then at Lujizhi Technology Group, where he transitioned from an investor to a company manager, successfully leading the company to the Hong Kong stock market [3]. Group 2: Role at Zhendong Pharmaceutical - In April 2022, Wang Zheyu returned to the pharmaceutical sector as the General Manager of the Strategy Department at Zhendong Pharmaceutical, overseeing legal affairs and strategic planning [3]. - By May 2023, he was promoted to Vice President and Board Secretary, taking on significant responsibilities as the company's spokesperson and compliance officer [4]. Group 3: Company Challenges and Developments - During Wang Zheyu's tenure as Board Secretary, Zhendong Pharmaceutical faced a significant arbitration case related to product quality issues, resulting in a total compensation payment of 500 million yuan to Langdi Pharmaceutical [6][7]. - The company also received a regulatory letter from the Shanxi Securities Regulatory Bureau regarding undisclosed fund occupation by the controlling shareholder, amounting to 51.3 million yuan [8][9]. - Despite these challenges, Zhendong Pharmaceutical's market value increased from 58.67 billion yuan in May 2023 to 60.73 billion yuan by January 2026 [10][11]. Group 4: Financial Performance - For the first three quarters of the previous year, Zhendong Pharmaceutical reported revenues of 2.215 billion yuan, a year-on-year decrease of 2.42%, and a net profit of 20.36 million yuan, down 49.25% [16]. - However, the company showed a strong performance in the third quarter, achieving revenues of 758 million yuan and a net profit of 124.33 million yuan, representing a year-on-year increase of 31.34% [16].

Group 1 - The "2025 Financial Annual Conference" held in Beijing focused on high-quality development of listed companies, emphasizing resilience and growth through cycles, with participation from over 200 listed companies and various industry leaders [1] - The "Golden Intelligence Award" recognized over 140 companies, including Haier Smart Home and Dongpeng Beverage, from more than 8,000 A-share, Hong Kong stock, and Chinese concept stock companies, highlighting their exemplary high-quality development [1] - A roundtable discussion on "New Era of Medicine" addressed key industry trends, including the localization of high-end medical equipment and global development paths, featuring insights from industry leaders and investment representatives [1] Group 2 - The development of the medical industry is an evolving process, with no definitive "best opportunity," and investments should be made with a forward-looking approach rather than chasing trends [3] - The historical context of the domestic pharmaceutical market shows a shift from generics to a focus on innovation, with policy changes impacting company strategies and emphasizing the need to address unmet market demands [3] - Future development directions in the pharmaceutical industry include research on drug resistance, enhancing drug efficacy, improving medication safety, and increasing patient adherence [4] Group 3 - The Chinese pharmaceutical industry is transitioning towards independent innovation, moving away from imitation and rapid following, which has increased market competition risks [5] - Global pharmaceutical companies have established comprehensive innovation ecosystems, and Chinese companies are beginning to adopt similar models, enhancing their innovation capabilities and global market influence [5] - The collaboration models between domestic and international pharmaceutical companies are evolving, reflecting the continuous improvement of China's biopharmaceutical innovation capacity [5] Group 4 - The pace of development in the medical industry remains constant, with changes occurring in market participants and innovation models across different stages [6]

Core Viewpoint - Zhejiang Jiuzhou Pharmaceutical Co., Ltd. is investing in Jiaxing Longfeng Venture Capital Partnership (Limited Partnership) through its wholly-owned subsidiary, with a total investment amount of RMB 77 million, of which Jiuzhou's contribution is RMB 10 million, accounting for 12.987% of the total [2][4]. Investment Overview - The investment is aimed at sectors related to new drug development and medical device research, focusing on high-quality emerging medical enterprises, including but not limited to new drugs, innovative drugs, medical devices, medical services, diagnostics, biotechnology, and pharmaceutical outsourcing research [2][12]. - The total subscribed capital of the partnership is RMB 77 million, which includes Jiuzhou's investment [4][12]. Partnership Agreement Details - The partnership agreement involves multiple partners, including Shihezi Longtai Equity Investment Management Partnership (Limited Partnership) and others, with Jiuzhou's subsidiary as a limited partner [4][5]. - The partnership has a duration of 6 years, with an investment period of 1.5 years and an exit period of 4.5 years [14]. - The management fee is set at 2% per year based on the total paid-in capital, with no management fee during the extension period [17]. Financial Impact and Strategic Alignment - This investment aligns with the company's overall development strategy and aims to leverage the expertise of professional investment management institutions to expand investment channels and generate returns [21]. - The investment is not expected to have a significant impact on the company's financial and operational status, complying with relevant laws and regulations [21].

Core Viewpoint - Jiuzhou Pharmaceutical (603456.SH) announced its subsidiary Hongzhou Investment's participation in a partnership to invest in Jiaxing Longfeng Venture Capital Partnership, focusing on the pharmaceutical sector, particularly in new drug and medical device development [1] Investment Details - The total committed capital for the partnership is RMB 77 million, with Hongzhou Investment contributing RMB 10 million, representing 12.987% of the total [1] - The investment will primarily target high-quality emerging medical enterprises, including but not limited to new drugs, innovative drugs, medical devices, medical services, diagnostics, biotechnology, and pharmaceutical outsourcing research and development [1]

Core Insights - The 2025 Analyst Conference highlighted the potential for a bull market in A-shares, attracting global capital inflows [1][3] - The event gathered over 300 industry experts to discuss future opportunities in the Chinese capital market [1][3] Investment Strategy - The pharmaceutical sector is expected to exhibit a "dual strength" characteristic in 2025, with leading companies maintaining robust performance while small-cap firms with technological breakthroughs also showing promise [1][3] - Analysts recommend a "core leaders and growth enhancers" strategy, focusing on strong companies while also investing in high-growth small-cap stocks to achieve a balance of stability and flexibility [1][3] Focus Areas for 2026 - Two main investment themes were emphasized: 1. **Innovation-Driven Theme**: Innovative drugs and their supply chains are seen as key long-term growth drivers, closely linked to market risk appetite [2][5] 2. **Turnaround Theme**: Certain sub-sectors like medical devices, traditional Chinese medicine, and consumer healthcare are showing signs of recovery, making them suitable for defensive positioning during market fluctuations [2][5] Market Dynamics - The valuation of innovative drugs is highly correlated with market sentiment towards technology stocks, necessitating a dynamic investment perspective [2][5] - The internal rotation within the pharmaceutical sector is expected to balance between "growth (innovative drugs)" and "safety (turnaround)" depending on market conditions [2][5]

Overall Situation - The pharmaceutical sector experienced a revenue decline of 2% and a net profit drop of 1% in the first three quarters of 2025, with a further decline in net profit of 3% in Q3 2025 [1][2] - The innovative drug segment showed strong revenue growth in Q3 2025, particularly in Bio-Pharma, CXO, and upstream sectors, while overall revenue growth has remained flat or slightly declining since Q1 2023 [1][3] Performance by Sub-Sectors - **Pharma**: Revenue decreased by 1% YoY in Q3 2025, with a significant drop in net profit by 13% [2] - **Bio-Tech**: Revenue surged by 61% YoY in Q3 2025, indicating strong performance despite a net profit decline of 32% [2] - **Bio-Pharma**: Revenue growth of 18% YoY in Q3 2025, with net profit increasing by 151% [2] - **CXO**: Revenue growth of 10% YoY in Q3 2025, with net profit up by 51% [2] - **Upstream**: Revenue increased by 13% YoY in Q3 2025, with net profit rising by 49% [2] - **Medical Devices**: Revenue grew by 11% YoY in Q3 2025, while net profit increased by 8% [2] - **IVD**: Revenue declined by 11% YoY in Q3 2025, with a net profit drop of 17% [2] - **High-value Consumables**: Revenue growth of 8% YoY in Q3 2025, with net profit up by 3% [2] - **Low-value Consumables**: Revenue decreased by 6% YoY in Q3 2025, with a net profit decline of 19% [2] Future Outlook - **Innovative Drugs**: Q3 2025 is expected to be the most challenging quarter for many Pharma companies, but upcoming clinical data releases and new drug approvals in 2026 are anticipated to drive revenue and profit growth [3] - **CXO**: The sector is expected to recover, with external demand for CDMO services improving and domestic CRO demand stabilizing [5] - **Upstream Research Services**: Revenue growth is expected to continue as industry demand accelerates [6][7] - **Medical Devices**: The sector is projected to see continued improvement in Q4 2025, with inventory levels returning to normal and potential growth in high-value products [8] Investment Insights - The focus is shifting back to the fundamentals of the innovative drug industry, with a need for tangible actions from multinational corporations (MNCs) to validate their partnerships [4] - Investment opportunities may arise from companies with strong collaborations with MNCs, as their clinical pipelines gain recognition and valuation [4] - A diversified index-based approach is recommended for participating in the pharmaceutical sector, with specific ETFs focusing on innovative drugs and medical devices [9][10]

Core Insights - The 10th Pharmaceutical Innovation and Investment Conference has commenced in Nanjing, attracting nearly a thousand participants from academia, industry, and investment sectors, including leaders from renowned pharmaceutical companies [1][2] - The conference serves as a platform to explore global pharmaceutical innovation trends and has become a "barometer" for pharmaceutical innovation and investment in China since its inception in 2016 [1][2] Group 1: Conference Highlights - The conference features various sub-forums focusing on cutting-edge topics such as anti-tumor new drugs, gene and cell therapy, and AI in pharmaceutical research, along with discussions on commercial insurance and healthcare payment reforms [2] - A special session, "Nanjing Jiangbei New Area-Hong Kong Biopharmaceutical Industry Exchange Conference," facilitates in-depth discussions between Hong Kong representatives and local enterprises [2] Group 2: Industry Development - The Jiangbei New Area is emerging as a vibrant hub for the biopharmaceutical industry, with over 1,300 biopharmaceutical companies and a competitive ranking of 8th nationwide [3] - The area has seen significant achievements, including 402 listed drugs and 1,261 medical device products, with several innovative products being first in the world [3] - The local biopharmaceutical sector is attracting attention from the capital market, with multiple companies, including Yaojie Ankang and Weili Zhibo, recently listing on the Hong Kong Stock Exchange [3][4] Group 3: Future Opportunities - The choice of Jiangbei New Area as the conference venue reflects the growing number of projects and enterprises in the region, which is also home to the first national university technology transfer center for biomedicine [5] - The presence of industry leaders at the conference is expected to inject confidence and vitality into the local biopharmaceutical ecosystem, paving the way for new collaborations and projects [5]

Core Insights - The article discusses the unique opportunities in the pharmaceutical sector amidst market fluctuations, questioning whether innovative drugs have peaked and exploring hidden opportunities in Hong Kong stocks [1]. Event Overview - A closed-door salon focused on pharmaceutical investments will be held on October 30, 2025, in Shanghai, themed "Tide Rising in the East, Medicine Meets the Future," aimed at providing investment advisors with practical strategies for Q4 pharmaceutical investments [1][12]. Agenda Highlights - The event features a tight agenda addressing practical pain points for investment advisors: - **Top-Level Insights**: A session by Yang Song, covering a decade of China's innovative drug industry, helping attendees understand the investment value and current cycle position [3]. - **Tool Exploration**: Liu Jie will analyze investment opportunities in Hong Kong's innovative drug sector, discussing how to utilize ETFs for efficient exposure to the sector [4]. - **Practical Strategies**: Zhu Wei will share insights on transforming industry knowledge into tangible client returns, enhancing the professional value of investment advisors [5]. - **Interactive Discussion**: A group discussion will allow attendees to exchange experiences and address specific queries regarding opportunities in pharmaceutical stocks [6]. Value Proposition - The event aims to bridge the entire chain from industry research to investment strategy and client service [8]. - Attendees will interact with top experts from brokerage research, fund investment, and frontline advisory roles [9]. - Participants will gain specific investment insights for the pharmaceutical sector and Hong Kong market, along with networking opportunities with 100 outstanding peers in Shanghai [10].